Steve Lenier

Steve Lenier

Contributing Writer

Steve Lenier began a career in medical literature over 30 years ago. He has worked on a variety of publications and projects, and across a number of specialties. Since 2005 most of his time has been spent covering ophthalmology, both print and online.

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma

May 4 2021

The Myopia Management Market: ‘How Big is Big?’

“How big is big?” That was a question that Dwight Akerman, OD, MBA, FAAO, FBCLA, put to a panel of industry insiders at last week’s ...
Read More

April 28 2021

Despite Interruption, Pixium Vision Aims to Keep Moving Toward Commercializing Prima System

Despite a potential business arrangement with a fellow retinal prosthesis innovator falling apart in recent weeks, Paris-based Pixium Vision is working to stay on course ...
Read More

April 20 2021

Gyroscope Therapeutics Completes Financing to Advance Gene Therapy Candidate for GA

Gyroscope Therapeutics recently raised $148 million in a Series C financing to advance the clinical development of GT005, its lead investigational gene therapy, which is ...
Read More

March 16 2021

New Technology and Teamwork Are Key for Combining Forces

Science and teamwork are important factors for companies considering acquisitions, collaborations, or partnerships in the dry eye space. That was the consensus of corporate leaders ...
Read More

February 16 2021

Verana Health and Janssen Enter Real-World Data and Data Science Collaboration

Verana Health has entered into a research collaboration with Janssen Research & Development, a unit of Johnson & Johnson, that focuses on curating real-world data ...
Read More

January 5 2021

Looking Ahead to 2021, Finding Value in 2020’s Lessons

Robert Kissling, VP, medical affairs for Bausch + Lomb, says forced changes can be the mother of innovation. If so, then 2020 should have sired ...
Read More

December 1 2020

Awareness and Innovation May Address Underdiagnosed Dry Eye Population

Dry eye disease is notoriously underdiagnosed. It’s also a market with a strong upside potential. In a recent interview with OIS Weekly, internationally known anterior ...
Read More

November 24 2020

Reimbursement Will Guide Innovation in Glaucoma

In ophthalmic innovation, great ideas only go so far. Without a potential revenue stream, investors would leave great ideas at the bench. In glaucoma, however, ...
Read More

November 10 2020

Exploring Why Pharma Hesitates to Embrace Drug-Delivery Methodologies

Drug-delivery technologies typically aim to improve pharmacologic and therapeutic properties of already approved drugs, but pharmaceutical companies are sometimes hesitant to acquire, develop, or invest ...
Read More

October 28 2020

The Next Wave of Glaucoma Innovation: Moving Beyond MIGS

Part 2 of 2 Micro-invasive glaucoma surgery (MIGS) has been in the forefront of innovation in the glaucoma space, and while MIGS innovation still has ...
Read More

October 20 2020

COVID Can’t Lock Down Innovation in Glaucoma

Part 1 of 2 The global COVID-19 pandemic has caused some changes in how companies in the glaucoma space pursue new products and technology, but ...
Read More

October 14 2020

Ocular Therapeutix Makes Lots of Buzz. Wall Street Notices

Reporting positive top-line clinical trial results, initiating two other clinical trials, getting wider Medicare coverage of its lead product, resolving a regulatory warning letter, and ...
Read More